Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health (Nasdaq: GH) announced the approval of equity grants to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The grants include 233,603 restricted stock units (RSUs) to 123 employees and stock options to purchase 50,349 shares to three employees. The RSUs vest annually over three years, while the stock options, priced at $28.16 per share, vest one-third after one year and monthly thereafter over 24 months. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Guardant Health (Nasdaq: GH) ha annunciato l'approvazione di concessioni azionarie a nuovi dipendenti non esecutivi nell'ambito del suo Piano di Incentivi per l'Occupazione 2023. Le concessioni includono 233.603 unità azionarie riservate (RSU) destinate a 123 dipendenti e opzioni per acquistare 50.349 azioni per tre dipendenti. Le RSU maturano annualmente nell'arco di tre anni, mentre le opzioni, con un prezzo di $28.16 per azione, maturano un terzo dopo un anno e mensilmente per i successivi 24 mesi. Queste concessioni sono state effettuate in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivi all'occupazione.
Guardant Health (Nasdaq: GH) anunció la aprobación de concesiones de acciones a nuevos empleados no ejecutivos bajo su Plan de Incentivos para la Ocupación 2023. Las concesiones incluyen 233.603 unidades de acciones restringidas (RSUs) para 123 empleados y opciones de compra de 50.349 acciones para tres empleados. Las RSUs se consolidan anualmente durante tres años, mientras que las opciones de compra, con un precio de $28.16 por acción, se consolidan un tercio después de un año y mensualmente durante los 24 meses siguientes. Estas concesiones se realizaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como incentivos laborales.
Guardant Health (Nasdaq: GH)는 2023년 고용 유도 인센티브 보상 계획에 따라 새로운 비상 executive 직원들에게 주식 보조금 승인을 발표했습니다. 이 보조금에는 233,603개의 제한 주식 단위(RSU)가 123명의 직원에게 제공되며, 세 명의 직원에게는 50,349주의 주식 매수 옵션이 포함됩니다. RSU는 3년 동안 매년 상환되며, $28.16의 주당 가격으로 제시된 스톡 옵션은 1년 후 3분의 1이 상환되고, 이후 24개월 동안 매달 상환됩니다. 이 보조금은 고용 유도로서 Nasdaq 상장 규칙 5635(c)(4)에 따라 제공되었습니다.
Guardant Health (Nasdaq: GH) a annoncé l'approbation de concessions d'actions à de nouveaux employés non exécutifs dans le cadre de son Plan d'Incentives à l'Emploi 2023. Les concessions comprennent 233.603 unités d'actions restreintes (RSU) pour 123 employés et des options d'achat de 50.349 actions pour trois employés. Les RSU se libèrent annuellement sur trois ans, tandis que les options d'achat, fixées à $28.16 par action, se libèrent d'un tiers après un an et mensuellement par la suite pendant 24 mois. Ces concessions ont été faites conformément à la règle d'inscription Nasdaq 5635(c)(4) en tant qu'incitations à l'emploi.
Guardant Health (Nasdaq: GH) gab die Genehmigung von Aktienvergaben an neue nicht-executive Mitarbeiter im Rahmen seines Anreizplans für die Beschäftigung 2023 bekannt. Die Vergaben umfassen 233.603 eingeschränkte Aktieneinheiten (RSUs) für 123 Mitarbeiter und Optionen zum Kauf von 50.349 Aktien für drei Mitarbeiter. Die RSUs werden jährlich über drei Jahre fällig, während die Optionen, die mit $28.16 pro Aktie bewertet sind, nach einem Jahr zu einem Drittel und danach monatlich über 24 Monate fällig werden. Diese Vergaben wurden gemäß der Nasdaq-Börsennotierungsregel 5635(c)(4) als Beschäftigungsanreize getätigt.
- None.
- None.
Insights
The equity compensation grants represent a significant talent acquisition initiative by Guardant Health, with RSUs covering 233,603 shares granted to 123 employees and stock options for 50,349 shares to 3 employees. The exercise price of
This compensation structure indicates aggressive hiring in non-executive roles, suggesting business expansion. While the dilutive impact is moderate at about
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
One-third of the shares underlying each RSU award vest on an annual basis on the anniversary of the vesting commencement date, subject to each employee’s continued employment with Guardant as of each such vesting date. The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.
All stock options have an exercise price of
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113633438/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Melissa Marasco
press@guardanthealth.com
+1 650-647-3711
Source: Guardant Health, Inc.
FAQ
How many RSUs did Guardant Health (GH) grant to new employees in November 2024?
What is the exercise price of Guardant Health's (GH) stock options granted on November 8, 2024?
What is the vesting schedule for Guardant Health's (GH) RSUs granted in November 2024?
